Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Great West Life Assurance Co. Can

Great West Life Assurance Co. Can trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,407 shares of the medical research company’s stock after selling 1,140 shares during the period. Great West Life Assurance Co. Can owned approximately 0.06% of Charles River Laboratories International worth $6,434,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Victory Capital Management Inc. grew its holdings in Charles River Laboratories International by 348.8% during the 3rd quarter. Victory Capital Management Inc. now owns 642,805 shares of the medical research company’s stock worth $145,563,000 after acquiring an additional 499,581 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Charles River Laboratories International by 47.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,267,881 shares of the medical research company’s stock worth $287,111,000 after buying an additional 409,339 shares during the last quarter. FMR LLC lifted its position in shares of Charles River Laboratories International by 18.2% in the 2nd quarter. FMR LLC now owns 1,945,690 shares of the medical research company’s stock worth $339,231,000 after buying an additional 299,655 shares during the last quarter. William Blair Investment Management LLC bought a new position in shares of Charles River Laboratories International in the 3rd quarter worth about $37,548,000. Finally, Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Charles River Laboratories International by 22.4% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 792,643 shares of the medical research company’s stock worth $138,197,000 after buying an additional 145,047 shares during the last quarter. 87.83% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently issued reports on the stock. Truist raised their price target on shares of Charles River Laboratories International from $237.00 to $256.00 in a research report on Tuesday, November 3rd. Morgan Stanley lifted their price objective on shares of Charles River Laboratories International from $245.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price objective for the company from $270.00 to $250.00 in a research report on Wednesday, December 16th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Charles River Laboratories International from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Finally, KeyCorp lifted their price objective on shares of Charles River Laboratories International from $233.00 to $256.00 and gave the company an “overweight” rating in a research report on Tuesday, November 24th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $215.20.

NYSE CRL opened at $249.86 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.45 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $12.43 billion, a PE ratio of 41.64, a price-to-earnings-growth ratio of 2.29 and a beta of 1.10. The company has a 50 day moving average price of $239.78 and a two-hundred day moving average price of $218.60. Charles River Laboratories International, Inc. has a 12-month low of $95.58 and a 12-month high of $257.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, October 29th. The medical research company reported $2.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.53. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. The business had revenue of $743.30 million during the quarter, compared to analysts’ expectations of $715.63 million. During the same period in the previous year, the company earned $1.69 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 11.3% on a year-over-year basis. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 7.86 EPS for the current year.

In related news, CEO James C. Foster sold 22,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $232.38, for a total transaction of $5,112,360.00. Following the transaction, the chief executive officer now owns 209,777 shares of the company’s stock, valued at $48,747,979.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard F. Wallman bought 1,150 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were bought at an average cost of $232.96 per share, for a total transaction of $267,904.00. Following the transaction, the director now directly owns 31,715 shares of the company’s stock, valued at approximately $7,388,326.40. The disclosure for this purchase can be found here. Insiders sold 30,889 shares of company stock valued at $7,307,020 over the last 90 days. 1.90% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is the Stochastic Momentum Index (SMI)?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.